<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ceftazidime and avibactam: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet"/></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ceftazidime and avibactam: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ceftazidime and avibactam: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="100323" href="/d/html/100323.html" rel="external">see "Ceftazidime and avibactam: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="121356" href="/d/html/121356.html" rel="external">see "Ceftazidime and avibactam: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F27736283"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Avycaz</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F27265642"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Cephalosporin Combination</li></ul></div>
<div class="block doa drugH1Div" id="F27736949"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosage recommendations are expressed as total grams of the ceftazidime/avibactam combination. Not recommended for routine empiric use. Reserve use for patients with or at risk for certain extensively drug-resistant gram-negative pathogens (nonsusceptible to ≥1 agent in all but 2 or fewer antimicrobial classes) (eg, carbapenem-resistant Enterobacterales, <i>P. aeruginosa</i> with difficult-to-treat resistance [DTR-<i>P. aeruginosa</i>]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35439291','lexi-content-ref-21793988','lexi-content-ref-33177185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35439291','lexi-content-ref-21793988','lexi-content-ref-33177185'])">Ref</a></span>). Some experts extend infusion time (ie, over 3 hours instead of standard 2 hours) for infections caused by carbapenem-resistant Enterobacterales, DTR-<i>P. aeruginosa</i>, and <i>S. maltophilia</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34864936','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34864936','lexi-content-ref-35439291'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2.5 g every 8 hours in combination with metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26962078','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26962078','lexi-content-ref-28085573'])">Ref</a></span>). Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29090866','lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29090866','lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58f09831-e1d9-4d13-a555-4196b8a7ce81">Pneumonia, hospital-acquired or ventilator-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired or ventilator-associated (alternative agent): IV: </b>2.5 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29254862']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29254862'])">Ref</a></span>). Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0dc8c99e-5200-48dc-a3c4-2ab11d9c2d8d">
<i>Stenotrophomonas maltophilia</i> infection, multidrug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stenotrophomonas maltophilia infection, multidrug-resistant (off-label use): IV: </b>2.5 g every 8 hours; use in combination with aztreonam (administered at the same time, if possible) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33870895','lexi-content-ref-34864936','lexi-content-ref-27551008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33870895','lexi-content-ref-34864936','lexi-content-ref-27551008'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2.5 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35439291','lexi-content-ref-27313268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35439291','lexi-content-ref-27313268'])">Ref</a></span>). Switch to an appropriate oral regimen once symptoms improve, if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991835"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Dosage recommendations are expressed as total grams of the ceftazidime/avibactam combination.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30221827','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30221827','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Estimation of renal function for the purpose of drug dosing should be done using the Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;50 to &lt;130 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;30 to 50 mL/minute: 1.25 g every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;15 to 30 mL/minute: 0.94 g every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;5 to 15 mL/minute: 0.94 g every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≤5 mL/minute: 0.94 g every 48 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2.5 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30670413','lexi-content-ref-33687300','lexi-content-ref-32015049','lexi-content-ref-30351195']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30670413','lexi-content-ref-33687300','lexi-content-ref-32015049','lexi-content-ref-30351195'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (~57% ceftazidime; 55% avibactam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27402250','lexi-content-ref-31109983','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27402250','lexi-content-ref-31109983','lexi-content-ref-Manu.1'])">Ref</a></span>)): 0.94 g every 24 hours; in patients with minimal residual kidney function and less severe infections, may consider administering 0.94 g every 48 hours. When scheduled dose falls on a dialysis day, administer after hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 0.94 g every 24 hours; in patients with minimal residual kidney function and less severe infections, may consider administering 0.94 g every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.25 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31109983','lexi-content-ref-28416553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31109983','lexi-content-ref-28416553'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b></p>
<p style="text-indent:-2em;margin-left:6em;">On PIRRT days: 1.25 g every 12 hours (administer 1 of the twice-daily doses after PIRRT session). Patients receiving prolonged daily treatments (eg, 12 hours a day) may require dosing every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">On non-PIRRT days: Dose as for CrCl ≤15 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989130"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F27736950"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F53125134"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="121356" href="/d/html/121356.html" rel="external">see "Ceftazidime and avibactam: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Avycaz (ceftazidime and avibactam) is a combination product; each 2.5 <b>g</b> vial contains 2 <b>g</b> ceftazidime and 0.5 <b>g</b> avibactam sodium in a 4:1 ratio. Dosage recommendations are based on the <b>ceftazidime</b> component. Dosing presented is based on traditional infusion method (IV infusion over 2 hours).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02b4604f-7121-4a88-88dd-a5008cafb941">Intra-abdominal infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated (cIAI):</b>
<b>Note: </b>Use in combination with metronidazole. The manufacturer recommends treating for 5 to 14 days depending upon severity and clinical response; a 5-day duration following source control is recommended for pediatric patients in guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 to &lt;6 months: IV: 40 mg ceftazidime/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents &lt;18 years: IV: 50 mg ceftazidime/kg/dose every 8 hours; maximum dose: 2,000 mg ceftazidime/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: 2,000 mg ceftazidime every 8 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (cUTI) (including pyelonephritis): Note:</b> The manufacturer recommends treating for 7 to 14 days depending upon severity and clinical response; durations as short as 6 to 10 days may be appropriate in children ≥2 years and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21873693','lexi-content-ref-36009990','lexi-content-ref-32364593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21873693','lexi-content-ref-36009990','lexi-content-ref-32364593'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infant ≥3 to &lt;6 months: IV: 40 mg ceftazidime/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents &lt;18 years: IV: 50 mg ceftazidime/kg/dose every 8 hours; maximum dose: 2,000 mg ceftazidime/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: 2,000 mg ceftazidime every 8 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="07d4d020-4a78-4131-987b-810a6aabb990">Pneumonia, hospital-acquired and ventilator-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired and ventilator-associated (HAP/VAP): Note:</b> The manufacturer recommends treating for 7 to 14 days; 7-day treatment durations are recommended in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infant ≥3 to &lt;6 months: IV: 40 mg ceftazidime/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents &lt;18 years: IV: 50 mg ceftazidime/kg/dose every 8 hours; maximum dose: 2,000 mg ceftazidime/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: IV: 2,000 mg ceftazidime every 8 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53125145"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosage recommendations are based on the <b>ceftazidime</b> component.</p>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥3 months and Children &lt;2 years: There are no dosage adjustments provided in the manufacturer's labeling; insufficient data to provide any recommendations for use in patients with eGFR &lt;50 mL/minute/1.73 m<sup>2</sup>; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents &lt;18 years: IV: <b>Note:</b> Use bedside Schwartz formula to estimate renal function for the purpose of drug dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 31 to 50 mL/minute/1.73 m<sup>2</sup>: 25 mg ceftazidime/kg/dose every 8 hours; maximum dose: 1,000 mg ceftazidime/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 16 to 30 mL/minute/1.73 m<sup>2</sup>: 19 mg ceftazidime/kg/dose every 12 hours; maximum dose: 750 mg ceftazidime/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 6 to 15 mL/minute/1.73 m<sup>2</sup>: 19 mg ceftazidime/kg/dose every 24 hours; maximum dose: 750 mg ceftazidime/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≤5 mL/minute/1.73 m<sup>2</sup>: 19 mg ceftazidime/kg/dose every 48 hours; maximum dose: 750 mg ceftazidime/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): Administer after hemodialysis on dialysis days; base dose upon patient's estimated renal function (eg, eGFR 6 to 15 mL/minute/1.73 m<sup>2</sup> or eGFR ≤5 mL/minute/1.73 m<sup>2</sup>). Approximately 55% (based on a ceftazidime 1,000 mg dose and avibactam 100 mg dose) is removed following a 4-hour dialysis session.</p>
<p style="text-indent:-2em;margin-left:2em;">Adolescents ≥18 years: IV: <b>Note:</b> Use Cockcroft-Gault formula to estimate renal function for the purpose of drug dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 31 to 50 mL/minute: 1,000 mg ceftazidime every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 16 to 30 mL/minute: 750 mg ceftazidime every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 6 to 15 mL/minute: 750 mg ceftazidime every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤5 mL/minute: 750 mg ceftazidime every 48 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): Administer after hemodialysis on dialysis days; base dose upon patient's estimated renal function (eg, CrCl 6 to 15 mL/minute or CrCl ≤5 mL/minute). Approximately 55% (based on a ceftazidime 1,000 mg dose and avibactam 100 mg dose) is removed following a 4-hour dialysis session.</p></div>
<div class="block dohp drugH1Div" id="F53125213"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants ≥3 months, Children, and Adolescents: No dosage adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F27767460"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see ceftazidime monograph.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hematologic &amp; oncologic: Positive direct coombs test (3% to 21%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Injection site phlebitis (children and adolescents: &gt;3%; adults: &lt;1%), skin rash (children and adolescents: &gt;3%; adults: &lt;1%), pruritus (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (&gt;3%), diarrhea (≥3%), nausea (3%), constipation (2%), upper abdominal pain (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acute renal failure, anxiety, candidiasis,<i> Clostridioides difficile-</i>associated diarrhea, dysgeusia, hypokalemia, increased gamma-glutamyl transferase, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, leukopenia, maculopapular rash, nephrolithiasis, renal insufficiency, thrombocythemia, thrombocytopenia, urticaria</p></div>
<div class="block coi drugH1Div" id="F27265645"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known serious hypersensitivity to ceftazidime, avibactam, other cephalosporins, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F27736830"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam drugs. Before initiating therapy, carefully investigate previous penicillin, cephalosporin, or carbapenem hypersensitivity. Use caution if given to a patient with a penicillin or other beta-lactam allergy; cross sensitivity has been established. If an allergic reaction occurs, discontinue and institute appropriate management.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Severe neurological reactions have been reported with ceftazidime, including asterixis, coma, encephalopathy, myoclonus, neuromuscular excitability, seizures, and nonconvulsive status epilepticus. Risk may be increased in the presence of renal impairment; ensure dose adjusted for renal function. Discontinue therapy if patient develops neurotoxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: In a complicated intra-abdominal infection clinical trial, adult patients with a CrCl of 30 to 50 mL/minute had lower clinical cure rates than those with CrCl &gt;50 mL/minute; however, these patients received a daily dose that was 33% lower than what is currently recommended for patients with this degree of renal impairment. Decreased clinical response was <b>not</b> seen in patients with a baseline CrCl of 30 to 50 mL/minute in complicated UTI clinical trials. Monitor renal function at baseline and at least daily in adult and pediatric patients with changing renal function. Adjust the dose accordingly.</p></div>
<div class="block foc drugH1Div" id="F27736284"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avycaz: Ceftazidime 2 g and avibactam 0.5 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F27736282"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F28326121"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Avycaz Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 (2-0.5) g (per each): $452.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F27736954"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer by intermittent infusion over 2 hours. Some experts extend infusion time to 3 hours for infections caused by carbapenem-resistant Enterobacterales, <i>P. aeruginosa</i> with difficult-to-treat resistance, and <i>S. maltophilia</i> (IDSA [Tamma 2022a]; IDSA [Tamma 2022b]).</p></div>
<div class="block admp drugH1Div" id="F53125219"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Administer by intermittent IV infusion over 2 hours.</p></div>
<div class="block use drugH1Div" id="F27265644"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infections:</b> Treatment of complicated intra-abdominal infections (cIAI) in adult and pediatric patients ≥3 months of age, in combination with metronidazole, caused by <i>Citrobacter freundii</i> complex, <i>Enterobacter cloacae</i>, <i>Escherichia coli</i>, <i>Klebsiella oxytoca</i>, <i>Klebsiella pneumoniae</i>, <i>Proteus mirabilis</i>, and <i>Pseudomonas aeruginosa</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired and ventilator-associated:</b> Treatment of hospital-acquired bacterial pneumonia and ventilator-associated (HAP/VAP) bacterial pneumonia in adult and pediatric patients ≥3 months of age caused by ceftazidime/avibactam-susceptible <i>K. pneumoniae</i>, <i>E. cloacae</i>, <i>E. coli</i>, <i>Serratia marcescens</i>, <i>P. mirabilis</i>, <i>P. aeruginosa</i>, and <i>Haemophilus influenzae</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):</b> Treatment of complicated urinary tract infections (including pyelonephritis) in adult and pediatric patients ≥3 months of age, caused by <i>C. freundii</i> complex, <i>E. cloacae</i>, <i>E. coli</i>, <i>K. pneumoniae</i>, <i>P. mirabilis</i>, and <i>P. aeruginosa</i>.</p></div>
<div class="block off-label drugH1Div" id="F57936094"><span class="drugH1">Use: Off-Label: Adult</span><p>Stenotrophomonas maltophilia infection</p></div>
<div class="block cyt drugH1Div" id="F27275624"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F27275621"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): May diminish the therapeutic effect of CefTAZidime. Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Avibactam.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F27736827"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies conducted with ceftazidime; adverse events have been observed in some animal reproduction studies conducted with avibactam.</p></div>
<div class="block brc drugH1Div" id="F27736829"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Ceftazidime is excreted in breast milk. It is not known if avibactam is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F27736956"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs of anaphylaxis during first dose. Monitor renal function at baseline in all patients, and at least daily in patients with changing renal function.</p></div>
<div class="block pha drugH1Div" id="F27736940"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Ceftazidime inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p>
<p style="text-indent:-2em;margin-left:2em;">Avibactam inactivates some beta-lactamases and protects ceftazidime from degradation.</p></div>
<div class="block phk drugH1Div" id="F27736942"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single dose: </i>Adults: Mean: Ceftazidime: 18.1 L; Avibactam: 23.2 L</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Multiple dose:</i> Adults: Mean: Ceftazidime: 17 L; Avibactam: 22.2 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Ceftazidime: &lt;10%; Avibactam: 5.7% to 8.2%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Ceftazidime: ~80% to 90% of dose eliminated as unchanged drug; Avibactam: Not metabolized</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single dose:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Ceftazidime:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥6 years to &lt;12 years: Median: 1.6 hours (0.9 to 1.8 hours) (Bradley 2016)</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Median: 1.7 hours (0.9 to 2.8 hours) (Bradley 2016)</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: Mean: 3.27 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Avibactam:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥6 years to &lt;12 years: Median: 1.7 hours (0.9 to 2 hours) (Bradley 2016)</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Median: 1.6 hours (0.9 to 2.8 hours) (Bradley 2016)</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: Mean: 2.22 hours</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Multiple dose:</i> Adults: Mean: Ceftazidime: 2.76 hours; Avibactam: 2.71 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Ceftazidime: Urine (~80% to 90% as unchanged drug); Avibactam: Urine (97%)</p></div>
<div class="block phksp drugH1Div" id="F51192707"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Half-life increases in patients with impaired renal function; AUC of avibactam increases 2.6-fold, 3.8-fold, and 7-fold in patients with mild, moderate or severe renal impairment, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Ceftazidime (data on monotherapy for susceptible organisms): Time dependent; associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC):</p>
<p style="text-indent:-2em;margin-left:8em;">Organism specific: Gram-negative bacteria (including <i>P. aeruginosa)</i>: Goal: 35% to 40% <i>f</i>T &gt; MIC (bacteriostatic in vitro); 60% to 70% <i>f</i>T &gt; MIC (bactericidal in vitro); ~45% to 53% <i>f</i>T &gt; MIC (microbiological response) (Craig 1995; MacVane 2014; Muller 2013).</p>
<p style="text-indent:-2em;margin-left:8em;">Population specific: In critically ill patients in the ICU, minimum goal: ≥50% <i>f</i>T &gt; MIC; preferred goal: ≥100% <i>f</i>T &gt; MIC (Abdul-Aziz 2020; Al-Shaer 2020; Roberts 2014); some experts favor ≥100% <i>f</i>T &gt;4 times the MIC (Guilhaumou 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Ceftazidime (in combination with avibactam): Interrelationship between ceftazidime exposure, avibactam exposure, MIC, and efficacy is not fully elucidated; at avibactam exposures that were associated with bacteriostatic and bactericidal activity, mean ceftazidime <i>f</i>T &gt; MIC (ceftazidime MIC in the presence of a fixed avibactam concentration): ~50% (Berkhout 2015; Nichols 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">Avibactam (in combination with ceftazidime): Time dependent, associated with <i>f</i>T &gt; threshold concentration (threshold concentration: 1 mg/L); goal: ≥ ~20% to 50% (Berkhout 2015; Coleman 2014; Crass 2019; Nichols 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Generally little to no postantibiotic effect (Berkhout 2021; Pillar 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug concentrations in patients with normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients (hospitalized): Single dose (2-hour infusion): C<sub>max</sub> (peak): IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and children 3 months to &lt;2 years of age: Ceftazidime 50 mg/avibactam 12.5 mg per kg: Ceftazidime: 91.7 mg/L; Avibactam: 16.3 mg/L (Bradley 2016).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to &lt;12 years of age: Ceftazidime 50 mg/avibactam 12.5 mg per kg (maximum ceftazidime 2,000 mg/avibactam 500 mg): Ceftazidime: ~80 mg/L; Avibactam: ~14 mg/L (Bradley 2016).</p>
<p style="text-indent:-2em;margin-left:8em;">Children and adolescents 12 to &lt;18 years of age: Ceftazidime 2,000 mg/avibactam 500 mg: Ceftazidime: 79.8 mg/L; Avibactam: 15.1 mg/L (Bradley 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: C<sub>max</sub> (peak): IV:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Adult doses are expressed as the combined amount of ceftazidime and avibactam.</p>
<p style="text-indent:-2em;margin-left:8em;">Single dose, 30-minute infusion (healthy volunteers): 2.5 g: Ceftazidime: 93.17 mg/L; Avibactam: 23.33 mg/L (Merdjan 2015).</p>
<p style="text-indent:-2em;margin-left:8em;">Steady state, 30-minute infusion (healthy volunteers): 2.5 g every 8 hours: Ceftazidime: 114.53 mg/L; Avibactam: 22.22 mg/L (Merdjan 2015).</p>
<p style="text-indent:-2em;margin-left:8em;">Steady state, 2-hour infusion (patients with nosocomial pneumonia, including ventilator-associated): 2.5 g every 8 hours: Ceftazidime: 61.9 to 79 mg/L; Avibactam: 12 to 15.5 mg/L (Li 2019).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49939944"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Torgena</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Avicrest | Cefactiv | Cipcza | Zavicefta</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Avycaz</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Avycaz</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Zavicefta</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and critically ill patient study groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. <i>Intensive Care Med</i>. 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32910809">
<a name="32910809"></a>Al-Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients. <i>J Antimicrob Chemother.</i> 2020;75(12):3644-3651. doi:10.1093/jac/dkaa359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/32910809/pubmed" id="32910809" target="_blank">32910809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873693">
<a name="21873693"></a>American Academy of Pediatrics (AAP) Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics</i>. 2011;128(3):595-610. doi:10.1542/peds.2011-1330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/21873693/pubmed" id="21873693" target="_blank">21873693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36009990">
<a name="36009990"></a>Autore G, Bernardi L, La Scola C, et al. Management of pediatric urinary tract infections: a Delphi study. <i>Antibiotics (Basel)</i>. 2022;11(8):1122. doi:10.3390/antibiotics11081122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/36009990/pubmed" id="36009990" target="_blank">36009990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avycaz.1">
<a name="Avycaz.1"></a>Avycaz (ceftazidime/avibactam) [prescribing information]. Madison, NJ: Allergan USA Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26525790">
<a name="26525790"></a>Berkhout J, Melchers MJ, van Mil AC, et al. Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection.<i> Antimicrob Agents Chemother.</i> 2015;60(1):368-375. doi:10.1128/AAC.01269-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/26525790/pubmed" id="26525790" target="_blank">26525790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33682636">
<a name="33682636"></a>Berkhout J, Melchers MJ, van Mil AC, Lagarde CM, Nichols WW, Mouton JW. Evaluation of the post-antibiotic effect in vivo for the combination of a β-lactam antibiotic and a β-lactamase inhibitor: ceftazidime-avibactam in neutropenic mouse thigh and lung infections. <i>J Chemother.</i> Published online March 6, 2021. doi:10.1080/1120009X.2021.1892365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/33682636/pubmed" id="33682636" target="_blank">33682636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27503642">
<a name="27503642"></a>Bradley JS, Armstrong J, Arrieta A, et al. Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients. <i>Antimicrob Agents Chemother</i>. 2016;60(10):6252-6259. doi:10.1128/AAC.00862-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/27503642/pubmed" id="27503642" target="_blank">27503642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25587996">
<a name="25587996"></a>Chalhoub H, Tunney M, Elborn JS, et al. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients. <i>J Antimicrob Chemother</i>. 2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/25587996/pubmed" id="25587996" target="_blank">25587996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24687507">
<a name="24687507"></a>Coleman K, Levasseur P, Girard AM, et al. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. <i>Antimicrob Agents Chemother.</i> 2014;58(6):3366-3372. doi:10.1128/AAC.00080-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/24687507/pubmed" id="24687507" target="_blank">24687507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7587056">
<a name="7587056"></a>Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. <i>Diagn Microbiol Infect Dis.</i> 1995;22(1-2):89-96. doi:10.1016/0732-8893(95)00053-d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/7587056/pubmed" id="7587056" target="_blank">7587056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30589457">
<a name="30589457"></a>Crass RL, Pai MP. Pharmacokinetics and pharmacodynamics of β-lactamase inhibitors. <i>Pharmacotherapy</i>. 2019;39(2):182-195. doi:10.1002/phar.2210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/30589457/pubmed" id="30589457" target="_blank">30589457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30670413">
<a name="30670413"></a>Das S, Li J, Riccobene T, et al. Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia. <i>Antimicrob Agents Chemother</i>. 2019;63(4):e02187-18. doi:10.1128/AAC.02187-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/30670413/pubmed" id="30670413" target="_blank">30670413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33870895">
<a name="33870895"></a>Diarra A, Pascal L, Carpentier B, et al Successful use of avibactam and aztreonam combination for a multiresistant Stenotrophomonas maltophilia bloodstream infection in a patient with idiopathic medullary aplasia. <i>Infect Dis Now.</i> 2021;51(7):637-638. doi:10.1016/j.idnow.2021.01.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/33870895/pubmed" id="33870895" target="_blank">33870895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team:Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc,FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32364593">
<a name="32364593"></a>Fox MT, Amoah J, Hsu AJ, Herzke CA, Gerber JS, Tamma PD. Comparative effectiveness of antibiotic treatment duration in children with pyelonephritis. <i>JAMA Netw Open</i>. 2020;3(5):e203951. doi:10.1001/jamanetworkopen.2020.3951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/32364593/pubmed" id="32364593" target="_blank">32364593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33687300">
<a name="33687300"></a>Gatti M, Pea F. Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors. <i>Expert Rev Clin Pharmacol</i>. 2021;14(5):583-599. doi:10.1080/17512433.2021.1901574<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/33687300/pubmed" id="33687300" target="_blank">33687300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29090866">
<a name="29090866"></a>Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. <i>J Hepatobiliary Pancreat Sci.</i> 2018;25(1):3-16. doi:10.1002/jhbp.518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/29090866/pubmed" id="29090866" target="_blank">29090866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925922">
<a name="30925922"></a>Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). <i>Crit Care.</i> 2019;23(1):104. doi:10.1186/s13054-019-2378-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/30925922/pubmed" id="30925922" target="_blank">30925922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021">
<a name="Hooton.2021"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25716293">
<a name="25716293"></a>Harris PN, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? <i>Lancet Infect Dis</i>. 2015;15:475-485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/25716293/pubmed" id="25716293" target="_blank">25716293</a>]</span>
<span class="doi">10.1016/S1473-3099(14)70950-8</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30221827">
<a name="30221827"></a>Li J, Lovern M, Green ML, et al. Ceftazidime-avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups. <i>Clin Transl Sci.</i> 2019;12(2):151-163. doi:10.1111/cts.12585<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/30221827/pubmed" id="30221827" target="_blank">30221827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32015049">
<a name="32015049"></a>Li J, Lovern M, Riccobene T, et al. Considerations in the selection of renal dosage adjustments for patients with serious infections and lessons learned from the development of ceftazidime-avibactam. <i>Antimicrob Agents Chemother</i>. 2020;64(4):e02105-19. doi:10.1128/AAC.02105-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/32015049/pubmed" id="32015049" target="_blank">32015049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23391714">
<a name="23391714"></a>Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. <i>J Antimicrob Chemother</i>. 2013;68(5):1183-1192. doi:10.1093/jac/dks523<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/23391714/pubmed" id="23391714" target="_blank">23391714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24342637">
<a name="24342637"></a>MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. <i>Antimicrob Agents Chemother.</i> 2014;58(3):1359-1364. doi:10.1128/AAC.01463-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/24342637/pubmed" id="24342637" target="_blank">24342637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21793988">
<a name="21793988"></a>Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. <i>Clin Microbiol Infect</i>. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/21793988/pubmed" id="21793988" target="_blank">21793988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26962078">
<a name="26962078"></a>Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program.<i> Clin Infect Dis</i>. 2016;62(11):1380-1389. doi:10.1093/cid/ciw133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/26962078/pubmed" id="26962078" target="_blank">26962078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25813217">
<a name="25813217"></a>Merdjan H, Rangaraju M, Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. <i>Clin Drug Investig.</i> 2015;35(5):307-317. doi:10.1007/s40261-015-0283-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/25813217/pubmed" id="25813217" target="_blank">25813217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27402250">
<a name="27402250"></a>Merdjan H, Tarral A, Das S, Li J. Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment. <i>J Clin Pharmacol</i>. 2017;57(2):211-218. doi:10.1002/jcph.793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/27402250/pubmed" id="27402250" target="_blank">27402250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27551008">
<a name="27551008"></a>Mojica MF, Ouellette CP, Leber A, et al. Successful treatment of bloodstream infection due to metallo-β-lactamase-producing stenotrophomonas maltophilia in a renal transplant patient. <i>Antimicrob Agents Chemother</i>. 2016;60(9):5130-5134. doi:10.1128/AAC.00264-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/27551008/pubmed" id="27551008" target="_blank">27551008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23190766">
<a name="23190766"></a>Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. <i>J Antimicrob Chemother.</i> 2013;68(4):900-906. doi:10.1093/jac/dks468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/23190766/pubmed" id="23190766" target="_blank">23190766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610208">
<a name="29610208"></a>Nichols WW, Newell P, Critchley IA, Riccobene T, Das S. Avibactam pharmacokinetic/pharmacodynamic targets. <i>Antimicrob Agents Chemother.</i> 2018;62(6):e02446-17. doi:10.1128/AAC.02446-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/29610208/pubmed" id="29610208" target="_blank">29610208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27221329">
<a name="27221329"></a>Pillar CM, Stoneburner A, Shinabarger DL, Krause KM, Nichols WW. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.<i> Lett Appl Microbiol.</i> 2016;63(2):96-102. doi:10.1111/lam.12592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/27221329/pubmed" id="27221329" target="_blank">27221329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31109983">
<a name="31109983"></a>Pistolesi V, Morabito S, Di Mario F, Regolisti G, Cantarelli C, Fiaccadori E. A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy. <i>Antimicrob Agents Chemother</i>. 2019;63(8):e00583-19. doi:10.1128/AAC.00583-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/31109983/pubmed" id="31109983" target="_blank">31109983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429437">
<a name="24429437"></a>Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? <i>Clin Infect Dis.</i> 2014;58(8):1072-1083. doi:10.1093/cid/ciu027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/24429437/pubmed" id="24429437" target="_blank">24429437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med.</i> 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30351195">
<a name="30351195"></a>Stein GE, Smith CL, Scharmen A, et al. Pharmacokinetic and pharmacodynamic analysis of ceftazidime/avibactam in critically ill patients. <i>Surg Infect (Larchmt)</i>. 2019;20(1):55-61. doi:10.1089/sur.2018.141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/30351195/pubmed" id="30351195" target="_blank">30351195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34864936">
<a name="34864936"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing enterobacterales, carbapenem-resistant acinetobacter baumannii, and stenotrophomonas maltophilia infections.<i> Clin Infect Dis.</i> 2022a;74(12):2089-2114. doi:10.1093/cid/ciab1013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/34864936/pubmed" id="34864936" target="_blank">34864936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35439291">
<a name="35439291"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). <i>Clin Infect Dis</i>. 2022b;75(2):187-212. doi:10.1093/cid/ciac268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/35439291/pubmed" id="35439291" target="_blank">35439291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29254862">
<a name="29254862"></a>Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. <i>Lancet Infect Dis</i>. 2018;18(3):285-295. doi:10.1016/S1473-3099(17)30747-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/29254862/pubmed" id="29254862" target="_blank">29254862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27313268">
<a name="27313268"></a>Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. <i>Clin Infect Dis</i>. 2016;63(6):754-762. doi:10.1093/cid/ciw378<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/27313268/pubmed" id="27313268" target="_blank">27313268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28416553">
<a name="28416553"></a>Wenzler E, Bunnell KL, Bleasdale SC, Benken S, Danziger LH, Rodvold KA. Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration. <i>Antimicrob Agents Chemother</i>. 2017;61(7):e00464-17. doi:10.1128/AAC.00464-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/28416553/pubmed" id="28416553" target="_blank">28416553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33177185">
<a name="33177185"></a>Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-lactam-β-lactamase inhibitor combinations. <i>Clin Microbiol Rev</i>. 2020;34(1):e00115-e00120. doi:10.1128/CMR.00115-20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/33177185/pubmed" id="33177185" target="_blank">33177185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23371303">
<a name="23371303"></a>Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. <i>Drugs</i>. 2013;73(2):159-177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftazidime-and-avibactam-drug-information/abstract-text/23371303/pubmed" id="23371303" target="_blank">23371303</a>]</span>
<span class="doi">10.1007/s40265-013-0013-7</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 100152 Version 128.0</div></div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
